xnk1

XNK1, also known as NKTR-214, is an investigational immunotherapy drug developed by Nektar Therapeutics. It is a novel bifunctional fusion protein designed to activate both the innate and adaptive immune systems to fight cancer. XNK1 is engineered to bind to both the CD122 receptor, also known as the IL-2 receptor alpha subunit, which is present on activated T cells and NK cells, and to the CD25 receptor, the IL-2 receptor beta subunit. This dual binding is intended to preferentially stimulate effector T cells and NK cells while minimizing the activation of regulatory T cells, which can suppress anti-tumor immune responses. By targeting these specific receptors, XNK1 aims to enhance the body's natural ability to recognize and destroy cancer cells. Clinical trials are ongoing to evaluate the safety and efficacy of XNK1, often in combination with other cancer therapies such as checkpoint inhibitors. The research focuses on its potential application across various solid tumors.